[Autoimmune hemolytic anemia].
Autoimmune hemolytic anemias (AIHAs) are the most ancient and well known example of clinical autoimmunity. They may be still distinguished in two main groups, that is with "warm" or "cold" antibodies, according to the optimal temperature at which they react with the erythrocyte antigens in vivo and in vitro. There is also a subgroup where both kinds of autoantibodies coexist. AIHAs may be idiopathic or secondary. The immunologic techniques for the demonstration of the antibodies are well established, but one must remember that there are infrequent cases with negative DAT (Coombs) test when performed with conventional procedures. The fundamental concepts of therapy are discussed, and the detailed review of the principal procedures is performed, including blood transfusions (when and how), plasma exchanges, high-dose immunoglobulins, glycocorticosteroids, splenectomy, cytotoxic agents and stem cell transplantation, autologous and allogeneic.
Marmont
A
A
Dipartimento di Ematologia (DEMA), Ospedale San Martino, Genova.
Zanella
A
A
D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D000906:Antibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal; D001803:Blood Transfusion; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use
D000906:Antibodies; D015415:Biomarkers; D007166:Immunosuppressive Agents